Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Huoxue Decoction is a traditional Chinese medicine (TCM) formula based on the principle of "tonifying Qi and activating blood circulation" to treat conditions attributed to "Qi deficiency and blood stasis". [5] As a multi-herb decoction, its specific composition can vary, but core ingredients often include herbs like Astragalus (Huang Qi), Angelica (Dang Gui), and Salvia (Dan Shen). [1, 15] The provided clinical trial information and research articles indicate its investigation for a range of conditions, including preventing restenosis after percutaneous coronary intervention in coronary heart disease, treating diabetic nephropathy, and aiding recovery from cerebral infarction. [7, 12] Research suggests its mechanisms involve improving microcirculation, reducing inflammation, providing antioxidant effects, and regulating cellular processes like autophagy and apoptosis. [3, 5, 8] For instance, in diabetic nephropathy models, it has been shown to protect podocytes and ameliorate kidney damage by activating autophagy. [2, 3] In cardiovascular models, it improves cardiac function by inhibiting apoptosis and regulating calcium flux. [1, 15] One specific formulation mentioned in clinical trials is Qi-Shen Dan-Shao granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Huoxue Decoction.